Skip to navigation Skip to content



About this Medication
  • Brand Name: Mavenclad® (MAY-ven-klad)
  • Chemical Name: Cladribine (KLA-dri-been)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

This is an oral medication in tablet form.


Mavenclad® is a compound that targets certain types of white blood cells (lymphocytes) that drive the immune attack in MS. It temporarily reduces the number of both T and B lymphocytes without continuous suppression of the immune system.

Mavenclad® is approved by the FDA for adults with relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease. Because of its safety profile, use of Mavenclad is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS.
Click here to read the Prescribing Information for healthcare providers. 

Click here to read the Medication Guide for patients.


MS LifeLines®

Financial Assistance Program

MS LifeLines®

What You Need to Know About Mavenclad®

This video was created in Summer 2019 and features Aaron Miller, MD. To learn more about Mavenclad® and other disease modifying therapy options, download the Consensus on Disease Modifying Therapies.


© 2024 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.